Acquired by KemPharm in June 2022
ORPH - Orphazyme A/S
NASDAQ
->
Healthcare
->
Biotechnology
Copenhagen,
Denmark
Type: Equity
ORPH price evolution
ORPH
| (in millions $) | 30 Jun 2021 | 31 Dec 2020 | 30 Jul 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $334.18 | $726.93 | $123.59 | |
| Short term investments | ||||
| Net receivables | $61.91 | $51.23 | $19.14 | |
| Inventory | ||||
| Total current assets | $403.69 | $783.66 | $638.19 | $148.22 |
| Long term investments | ||||
| Property, plant & equipment | $13.93 | $19.55 | $19.79 | $17.59 |
| Goodwill & intangible assets | $2.19 | $12.45 | $10.54 | |
| Total noncurrent assets | $24.34 | $38.83 | $32.53 | |
| Total investments | ||||
| Total assets | $428.03 | $822.49 | $676.36 | $180.75 |
| Current liabilities | ||||
| Accounts payable | $98.98 | $72.14 | $58.77 | $32.39 |
| Deferred revenue | ||||
| Short long term debt | $35.99 | $37.01 | $12.81 | |
| Total current liabilities | $223.66 | $166.63 | $121.81 | $65.99 |
| Long term debt | $22.6 | $33.71 | $47.8 | $61.42 |
| Total noncurrent liabilities | $37.61 | $35.34 | $61.8 | |
| Total debt | $58.59 | $70.71 | $74.23 | |
| Total liabilities | $261.27 | $201.97 | $170.22 | $127.78 |
| Shareholders' equity | ||||
| Retained earnings | -$1953.95 | -$1502.92 | -$1132.51 | -$899.02 |
| Other shareholder equity | $0.53 | $0.99 | -$0.03 | $0.11 |
| Total shareholder equity | $166.76 | $620.52 | $52.97 | |
| (in millions $) | 31 Dec 2020 | 31 Dec 2019 | 30 Dec 2018 | 30 Dec 2017 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $726.93 | $123.59 | $394.71 | $631.74 |
| Short term investments | ||||
| Net receivables | $51.23 | $19.14 | $14.45 | $11.37 |
| Inventory | ||||
| Total current assets | $783.66 | $148.22 | $423.38 | $647.95 |
| Long term investments | ||||
| Property, plant & equipment | $19.55 | $17.59 | $1.94 | $1.85 |
| Goodwill & intangible assets | $12.45 | $10.54 | ||
| Total noncurrent assets | $38.83 | $32.53 | ||
| Total investments | ||||
| Total assets | $822.49 | $180.75 | $441.35 | $662.82 |
| Current liabilities | ||||
| Accounts payable | $72.14 | $32.39 | $18.09 | $13.44 |
| Deferred revenue | ||||
| Short long term debt | $37.01 | $12.81 | ||
| Total current liabilities | $166.63 | $65.99 | $52.99 | $47.12 |
| Long term debt | $33.71 | $61.42 | ||
| Total noncurrent liabilities | $35.34 | $61.8 | ||
| Total debt | $70.71 | $74.23 | ||
| Total liabilities | $201.97 | $127.78 | $53.1 | $47.12 |
| Shareholders' equity | ||||
| Retained earnings | -$1502.92 | -$899.02 | -$564.82 | -$338.22 |
| Other shareholder equity | $0.99 | $0.11 | $9.11 | $9.97 |
| Total shareholder equity | $620.52 | $52.97 | $388.25 | $615.7 |
| (in millions $) | 30 Jul 2021 | 30 Jan 2021 | 29 Jun 2020 | 30 Mar 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $83.49 | $83.49 | ||
| Selling, general & administrative | $39.29 | $39.29 | ||
| Total operating expenses | $122.78 | $122.78 | ||
| Operating income | -$122.78 | -$122.78 | ||
| Income from continuing operations | ||||
| EBIT | -$122.78 | -$122.78 | ||
| Income tax expense | -$0.99 | -$0.99 | ||
| Interest expense | -$3.98 | -$3.98 | ||
| Net income | ||||
| Net income | -$125.71 | -$125.71 | ||
| Income (for common shares) | -$125.71 | -$125.71 | ||
| (in millions $) | 31 Dec 2020 | 31 Dec 2019 | 30 Dec 2018 | 30 Dec 2017 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $361.28 | $285.41 | $194.39 | $97.56 |
| Selling, general & administrative | $247.25 | $50.54 | $37.26 | $33.49 |
| Total operating expenses | $608.53 | $335.95 | $231.65 | $131.04 |
| Operating income | -$608.53 | -$335.95 | -$231.65 | -$131.04 |
| Income from continuing operations | ||||
| EBIT | -$606.09 | -$335.64 | -$231.65 | -$131.04 |
| Income tax expense | -$1.92 | -$5.5 | -$5.5 | -$5.5 |
| Interest expense | $29.07 | $7.36 | -$2.82 | -$0.69 |
| Net income | ||||
| Net income | -$633.25 | -$337.5 | -$229.6 | -$126.2 |
| Income (for common shares) | -$633.25 | -$337.5 | -$229.6 | -$126.2 |
| (in millions $) | 30 Jul 2021 | 30 Jan 2021 | 29 Jun 2020 | 30 Mar 2020 |
|---|---|---|---|---|
| Net income | -$75.49 | -$97.01 | -$125.71 | -$125.71 |
| Operating activities | ||||
| Depreciation | $1.13 | $1.13 | ||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$61.88 | -$82.59 | -$102.08 | -$102.08 |
| Investing activities | ||||
| Capital expenditures | -$0.58 | -$0.58 | ||
| Investments | ||||
| Total cash flows from investing | -$0.13 | -$0.78 | -$0.88 | -$0.88 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | -$0.85 | -$0.85 | ||
| Total cash flows from financing | -$2.52 | $177.62 | $346.47 | $346.47 |
| Effect of exchange rate | $0.86 | -$1.82 | -$0.08 | -$0.08 |
| Change in cash and equivalents | -$63.66 | $92.43 | $243.43 | $243.43 |
| (in millions $) | 31 Dec 2020 | 31 Dec 2019 | 30 Dec 2018 | 30 Dec 2017 |
|---|---|---|---|---|
| Net income | -$633.25 | -$337.5 | -$229.6 | -$126.2 |
| Operating activities | ||||
| Depreciation | $5.2 | $3.8 | $1.37 | $0.75 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $28.11 | $2.55 | ||
| Total cash flows from operations | -$539.08 | -$326.82 | -$234.76 | -$95.43 |
| Investing activities | ||||
| Capital expenditures | -$2.37 | -$2.78 | -$0.74 | -$1.49 |
| Investments | ||||
| Total cash flows from investing | -$5.1 | -$3.29 | -$2.35 | -$1.49 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $1172.93 | $0.02 | ||
| Net borrowings | -$13.51 | $58.92 | $58.92 | $58.92 |
| Total cash flows from financing | $1159.42 | $58.94 | $58.94 | $714.3 |
| Effect of exchange rate | -$1.82 | $0.08 | $0.08 | |
| Change in cash and equivalents | $615.25 | -$271.16 | -$237.03 | $617.39 |
News
|
KemPharm (KMPH) Stock Up on Deal to Acquire Orphazyme for $12.8M
Zacks via Yahoo Finance
17 May 2022
|
|
KemPharm Acquires Battered Orphazyme's Arimoclomol Program For $13M
Benzinga via Yahoo Finance
16 May 2022
|
|
Orphazyme Withdraws European Application For Arimoclomol, Initiates Delisting Of Its ADSs
Benzinga via Yahoo Finance
22 Mar 2022
|
|
Dear ORPH Stock Fans, Mark Your Calendars for March 31
InvestorPlace
22 Mar 2022
|
|
30 Stocks Moving in Tuesday's Pre-Market Session
Benzinga
22 Mar 2022
|
|
Why Is Orphazyme (ORPH) Stock Up Today?
InvestorPlace
17 Mar 2022
|
|
Why Is OXY Stock Up Today? Does Warren Buffett's Berkshire Want to Buy Occidental Petroleum?
InvestorPlace
17 Mar 2022
|
|
22 Stocks Moving in Thursday's Pre-Market Session
Benzinga
17 Mar 2022
|
|
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.69% By Investing.com
Investing.com
11 Mar 2022
|
|
30 Stocks Moving in Friday's Pre-Market Session
Benzinga
11 Mar 2022
|
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 34.95M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 0.00 |
| Book/Share | 4.76 |
| Cash/Share | 9.56 |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.33 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.80 |
| Quick ratio | 1.80 |